



Alzheimer's Disease Genetics

Guest Editors:

Dr. Laura Ibanez

Dr. Justin Miller

Deadline for manuscript
submissions:

closed (30 November 2024)

Message from the Guest Editors

1. Genetic Variant Associations: Original research exploring the influence of specific rare and common genetic variants on Alzheimer's disease susceptibility and progression.
2. Genetic Biomarkers: Papers elucidating the use of genetic markers for early diagnosis, disease risk assessment and personalized treatment strategies.
3. Genetic Heterogeneity: Studies addressing the genetic heterogeneity of Alzheimer's disease and its implications for clinical practice.
4. Epigenetics, Gene Regulation and Gene Expression: Investigations into epigenetic mechanisms, gene regulatory processes and transcriptomic studies that are relevant to Alzheimer's disease pathogenesis.
5. Genetic Technologies: Articles focusing on how state-of-the-art technologies, including machine learning, improve Alzheimer's disease research.
6. Emerging and Established Therapeutic Strategies: Reviews or original research discussing novel therapeutic interventions targeting the genetic aspects of Alzheimer's disease, or how genetics relate to already-approved (or soon to be approved) therapies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)